TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02760797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emactuzumab
Description: Emactuzumab will be administered IV every 3 weeks (every cycle) during Part I and every 3 or 6 weeks (every cycle or every other cycle) during Part II.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emactuzumab
Description: Emactuzumab will be administered IV every 3 weeks (every cycle) during Part I and every 3 or 6 weeks (every cycle or every other cycle) during Part II.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7009789
Description: RO7009789 will be administered IV every 3 weeks (every cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7009789
Description: RO7009789 will be administered IV every 3 weeks (every cycle).
Study: NCT03074955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: leg wrapping with tension
Description: 1. Apply elastic bandages with tension to both legs before injecting propofol.~2. After 3 minutes, remove elastic bandages.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trendelenburg position
Description: 1. Apply Trendelenburg position positon of 10 degree after injectin propofol~2. After 3 minutes, change to supine position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trendelenburg position
Description: 1. Apply Trendelenburg position positon of 10 degree after injectin propofol~2. After 3 minutes, change to supine position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: leg wrapping without tension
Description: 1. Apply elastic bandages without tension to both legs before injecting propofol.~2. After 3 minutes, remove elastic bandages

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supine position
Description: 1.maintain supine position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supine position
Description: 1.maintain supine position
Study: NCT03849248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal scent cloth
Description: The babies assigned to the intervention group will have a cloth with their mother's scent on it placed under their heads.
Study: NCT04337801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: The acupressure for symptom management is performed by pressing and scrubbing-like manipulations at certain points on the acupuncture meridians.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo intervention involves touching to the Pericardium 6 and Large Intestine 4 points without pressing.
Study: NCT04289662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-924 LD
Description: Pitavastatin 2 mg / Ezetimibe 10 mg tables

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-924 HD
Description: Pitavastatin 4 mg / Ezetimibe 10 mg tables
Study: NCT02435446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cone-beam computed tomography
Description: Cone-beam computed tomography
Study: NCT01953107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Ferrous Fumarate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03722823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tucatinib
Description: 300mg oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: 300mg oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: 300mg oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: 300mg oral single dose
Study: NCT01665651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yougui granules
Description: Yougui granules is traditional Chinese patent medicine used to treatment patients with kidney Yang deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zuogui granules
Description: Zuogui granules is traditional Chinese patent medicine used to treatment patients with kidney Yin deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yougui granules placebo
Description: Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zuogui granules placebo
Description: Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
Study: NCT01039454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK598809 Capsules
Description: GSK598809 is being developed for the treatment of substance dependence and potentially other impulse control disorders.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK598809 Placebo Capsules
Description: Treatment of substance dependence and potentially other impulse control disorders.
Study: NCT03068884

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cathodal Transcranial direct current stimulation
Description: Cathodal transcranial direct current stimulation over the dorsolateral prefrontal cortex

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal Transcranial direct current stimulation
Description: Cathodal transcranial direct current stimulation over the dorsolateral prefrontal cortex

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Tyrosine
Description: Administration of 2 grams tyrosine

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: L-Tyrosine
Description: Administration of 2 grams tyrosine

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation (sham)
Description: Sham tDCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (sham)
Description: Sham tDCS

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cellulose (placebo)
Description: Administration of 2 grams cellulose

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Cellulose (placebo)
Description: Administration of 2 grams cellulose
Study: NCT03493321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRF with Theracal
Description: using the PRF which is a new technique with an bioactive material which is the Theracal to evaluate its effect upon the radicular pulp tissue
Study: NCT02568007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Study: NCT02736760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy using Methylaminolevulinate (MAL)
Description: In the Daylight photodynamic therapy arm the patients will apply a sunscreen to the whole face which is followed by lesion preparation of AKs. Following this, MAL will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours.~5 photodynamic therapy treatment sessions (visits 1-5) will be performed within 18 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: In the control group, cryosurgery as standard reference therapy will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. Cryosurgery of AK lesions will be investigated as standard reference therapy. Single freeze-thaw cryosurgery is performed using an open spraying procedure with liquid nitrogen with nozzle size C. After formation of an ice-ball of the required size, freeze time starts. Freeze time should lie between 5 s and 10 s.
Study: NCT00659022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neo-adjuvant treatment with bevacizumab
Description: neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the colorectal primary

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant treatment with capecitabine and oxaliplatin
Description: neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary
Study: NCT00683735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg once daily in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg once daily in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: up to 2000 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: up to 2000 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 500mg 1-0-0-0

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500mg 1-0-0-0
Study: NCT00603980

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled alprazolam 2 mg
Description: Inhaled Staccato alprazolam 2 mg + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled alprazolam 2 mg
Description: Inhaled Staccato alprazolam 2 mg + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled alprazolam 2 mg
Description: Inhaled Staccato alprazolam 2 mg + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled alprazolam 2 mg
Description: Inhaled Staccato alprazolam 2 mg + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled alprazolam 2 mg
Description: Inhaled Staccato alprazolam 2 mg + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled alprazolam 2 mg
Description: Inhaled Staccato alprazolam 2 mg + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled alprazolam 2 mg
Description: Inhaled Staccato alprazolam 2 mg + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled alprazolam 2 mg
Description: Inhaled Staccato alprazolam 2 mg + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled alprazolam 2 mg
Description: Inhaled Staccato alprazolam 2 mg + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled alprazolam 2 mg
Description: Inhaled Staccato alprazolam 2 mg + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled alprazolam 2 mg
Description: Inhaled Staccato alprazolam 2 mg + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled alprazolam 2 mg
Description: Inhaled Staccato alprazolam 2 mg + oral placebo
Study: NCT00659022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neo-adjuvant treatment with bevacizumab, capecitabine and oxaliplatin
Description: neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery of the colorectal primary
Study: NCT00647647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine Hydrochloride Tablets 250 mg
Description: 250mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamisil® Tablets 250 mg
Description: 250mg, single dose fasting
Study: NCT02884453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: Ibrutinib (PCI-32765) is a first-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of Bruton's tyrosine kinase (BTK) currently under development for the treatment of B-cell malignancies. Ibrutinib is being co-developed by Janssen Research \& Development, LLC and Pharmacyclics Inc.
Study: NCT00603980

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled alprazolam 2 mg
Description: Inhaled Staccato alprazolam 2 mg + oral placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 1 mg
Description: Oral alprazolam 1 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 1 mg
Description: Oral alprazolam 1 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 1 mg
Description: Oral alprazolam 1 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 1 mg
Description: Oral alprazolam 1 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 1 mg
Description: Oral alprazolam 1 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 1 mg
Description: Oral alprazolam 1 mg + Inhaled placebo
Study: NCT01769027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline+Antibiotic (penicillin/azithromycin)
Description: 12 weeks treatment with a combination of Sertraline (to a maximum of 200 mg/day) and an antibiotic (benzathine penicillin G 1.200.000 U every 3 weeks or, in case of allergy, azithromycin 500 mg/week.~Non-responder patients will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sertraline+placebo
Description: 12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and placebo
Study: NCT00683735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 100mg 1-0-0-0

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mg 1-0-0-0
Study: NCT01749761

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BioLogic RR
Description: Patients will be randomized to BP guided biofeedback arm which will entail regular hemodialysis with a software program turned on to allow frequent assessment of blood pressure and automated adjustments of the ultrafiltration rate based on these blood pressure measurements. The duration of this arm is 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis without biofeedback
Description: patients will be randomized to Standard HD (without biofeedback technology) for 8 weeks
Study: NCT01726023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Description: Ceftazidime-Avibactam powder for concentrate for solution for infusion 2000 mg/500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole
Description: Metronidazole 500mg/100ml solution for infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem powder for solution for infusion 1000mg
Study: NCT02601053

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dull movie
Description: A dull movie (duration approximately 90 minutes)
Study: NCT01769027

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
Study: NCT02477748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDX
Description: Immediate-release/slow-release,bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet PO, taken once daily for 10 weeks.
Study: NCT02601053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dull movie
Description: A dull movie (duration approximately 90 minutes)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scary (horrifying) movie
Description: A scary movie (duration approximately 90 minutes)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scary (horrifying) movie
Description: A scary movie (duration approximately 90 minutes)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart rate measurement
Description: Heart rate measurement using a actiheart device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart rate measurement
Description: Heart rate measurement using a actiheart device
Study: NCT02844010

Intervention type: OTHER
Intervention: weighing
Study: NCT04225286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human breast milk
Description: Intranasal human breast milk
Study: NCT00710099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: systemic absorption of sildenafil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroprussiate iontophoresis
Description: nitroprussiate iontophoresis
Study: NCT04154722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem Injection
Description: inj meropenum for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem Injection
Description: inj meropenum for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Powder
Description: syp azithromycin for10days
Study: NCT03896191

Intervention type: PROCEDURE
Intervention: Revision TKR surgery
Description: This study will follow the cohort of patients who have an unstable primary TKR with which they are dissatisfied. They will be assessed before and after their revision TKR surgery.

Intervention type: OTHER
Intervention: No intervention.
Description: This study will also make a case-control comparison between patients with a stable primary TKR and an unstable primary TKR.
Study: NCT03034161

Intervention type: DEVICE
Intervention: Thermal imaging
Description: Thermal imaging of the various stages of pressure ulcer will be analyzed to determine if a recognizable pattern of thermal distribution can be identified which can then be applied to identify patients at risk of developing pressure ulcers at an earlier stage in their hospital course.

Intervention type: DEVICE
Intervention: Thermal imaging
Description: Thermal imaging of the various stages of pressure ulcer will be analyzed to determine if a recognizable pattern of thermal distribution can be identified which can then be applied to identify patients at risk of developing pressure ulcers at an earlier stage in their hospital course.

Intervention type: DEVICE
Intervention: Thermal imaging
Description: Thermal imaging of the various stages of pressure ulcer will be analyzed to determine if a recognizable pattern of thermal distribution can be identified which can then be applied to identify patients at risk of developing pressure ulcers at an earlier stage in their hospital course.

Intervention type: DEVICE
Intervention: Thermal imaging
Description: Thermal imaging of the various stages of pressure ulcer will be analyzed to determine if a recognizable pattern of thermal distribution can be identified which can then be applied to identify patients at risk of developing pressure ulcers at an earlier stage in their hospital course.
Study: NCT00885677

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic CareLink® Network
Description: Continuous monitoring via a disease remote management system.~Patients of the Study group will receive a remote monitor and their device will be programmed to have wireless telemetry, Care Alerts, and the ability to transmit over the Medtronic CareLink® network. Clinical and device conditions will be then monitored continuously and alarms for the physician will be generated if a set of pre-defined potentially harming conditions should occur.
Study: NCT01404052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Subjects will be randomized to undergo either 5 sessions of active tDCS stimulation, or 5 sessions of sham tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2 and an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. Active stimulation will last for 20 minutes, while sham stimulation will only last for 30 seconds, mimicking the sensations during active stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Subjects will be randomized to undergo either 5 sessions of active tDCS stimulation, or 5 sessions of sham tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2 and an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. Active stimulation will last for 20 minutes, while sham stimulation will only last for 30 seconds, mimicking the sensations during active stimulation.
Study: NCT04403399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Initial 0.25 mg oral dose of varenicline administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final 0.5 mg BID oral varenicline administered for the remaining 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Initial 0.25 mg oral dose of varenicline administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final 0.5 mg BID oral varenicline administered for the remaining 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Initial placebo oral dose administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final placebo BID dosing administered orally for the remaining 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Initial placebo oral dose administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final placebo BID dosing administered orally for the remaining 3 weeks.
Study: NCT03800225

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repair
Description: Anterior ligament repair with internal brace.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repair
Description: Anterior ligament repair with internal brace.
Study: NCT04027257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit Together and Read (STAR)
Description: STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
Study: NCT00603980

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 1 mg
Description: Oral alprazolam 1 mg + Inhaled placebo
Study: NCT00498628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: Quetiapine fumarate- taken daily, for 12 weeks
Study: NCT02158481

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: A capsule containing both polyphenols and carotenoids
Study: NCT00498628

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03364504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: urine collection
Description: 3 urine collections during 24 hours
Study: NCT03868696

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: MUA with sham ultrasound
Description: Standard MUA with sham ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MUA with active ultrasound
Description: Standard MUA guided by ultrasound
Study: NCT01483170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tablets Fexinidazole
Description: Administration of 3 or 4 tablets of 600mg per day during 4 days (loading dose) then administration of 2 tablets of 600mg for 6 days Dosing in fed condition.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo fexinidazole